Local antihistamines

Clinical and Experimental Allergy

Volumn 26, Issue 10, 1996, Pages 1108-1111

  Trigg, C J ^a   Davies, R J ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; LEUKOTRIENE C4; LEVOCABASTINE;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; HISTAMINE H1 ANTAGONISTS; HUMANS; META-ANALYSIS;

EID: 0029853158     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.1996.tb00495.x     Document Type: Review

References (35)

1. Graf P, Juto J-E. Histamine sensitivity in the nasal mucosa during four-week use of oxymetazoline. Rhinology 1994; 32:123 6.
2. Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 1994; 94:134 6.
3. Chaweewan B, Jareonchai P, Dhorranintra B. A clinical comparison of cetirizine versus astemizole in perennial allergic rhinitis. Drug Invest 1993; 5:222 8.
4. Busse WW. Role of antihistamines in allergic disease. Ann Allergy 1994; 72:371 5.
5. Committee on Safety of Medicines. Ventricular arrythmias due to terfenadine and astemizole. Current Problems 1992; 35:1 2.
6. Bahmer FA. Topical levocabastine an effective alternative to oral antihistamines in seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 1995; 25:220 7.
7. Stokes TC, Feinberg G. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis. Clin Exp Allergy 1993; 23:791 4.
8. Abelson MB, George MA, Smith LM. Evaluation of 0.05% levocabastine versus 4% sodium cromoglycate in the allergen challenge model. Ophthalmology 1995; 102: 310 6.
9. K) relives ongoing symptoms of allergic conjunctivitis within 2 minutes. Allergy 1994; 49:637 40.
10. Nielsen, L., Johnsen CR, Bindslev-Jensen C, Poulsen LK. Efficacy of acrivastine in the treatment of allergic rhinitis during natural pollen exposure: onset of action. Allergy 1994; 49:630 6.
11. Vermeulen J, Mercer, M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Ped Allergy Immunol 1994; 5:209 13.
12. Frostad AB, Olsen AK. A comparison of topical levocabastine and sodium cromoglycate in the treatment of pollen-provoked allergic conjunctivitis. Clin Exp Allergy 1993; 23:406-9.
13. Sohoel P, Freng, BA. Kramer J et al. Topical levocabastine compared with orally-administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis. J Allergy Clin Immunol 1993; 92:73-81.
14. The Swedish GP Allergy Team. Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Allergy 1994; 49:611 5.
15. Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 1985; 16:318 22.
16. Fields DAS. Pillar J. Diamantis W et al. Inhibition by azelastine of nonallergic histamine release from rat peritoneal mast cells. J Allergy Clin Immunol 1984; 73:400 3.
17. Thomas KE, Oilier S, Ferguson H, Davies RJ. The effect of intranasal azelastine. Rhinolast. on nasal airways obstruction and sneezing following provocation testing with histamine and allergen. Clin Exp Allergy 1992; 22:642 7.
18. Weiler JM, Meltzer EO, Benson PM, Weiler K. Widlitz MD. Freitag J. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol 1994; 94:972 80.
19. Gastpar H, Nolte D. Aurich R et al. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy 1994; 49:152 8.
20. Davies RJ, Lund VJ, Harten-Ash. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinology 1993; 31:159 64.
21. Rombaut N, Bhatti JZ, Curran S, Hindmarch I. Effects of topical administration of levocabastine on psychomotor and cognitive function. Ann Allergy 1991; 67:75 9.
22. Ramachers U, Amon U, Wolff HH. Direct effects of second-generation H1-receptor antagonists on the activation of human basophils. Agents Actions 1994; 41: C45 6.
23. Naclerio RM. Effects of antihistamines on inflammatory mediators. Ann Allergy 1993; 71:292 5.
24. Little MM, Casale TB. Azelastine inhibits IgE-mediated human basophil histamine release. J Allergy Clin Immunol 1989; 83:862 5.
25. Bousquet J, Lebel B, Chanal I, Morel A, Michel FB. Antiallergic activity of H1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988; 82:881 7.
26. Holen E, Elsayed S, Nyfors A. The effect of H1-antagonists on peripheral blood mononuclear cells, adenoid cells and primary cell lines. APMIS 1995; 103:98-106.
27. Henocq E, Rihoux J-P. Does reversed type anaphylaxis in healthy subjects mimic a real allergic reaction? Clin Exp Allergy 1990; 20:269 72.
28. Ciprandi G, Buscaglia S, Marchesi E, Danzig M, Cuss F. Canonica GW. Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Immunol 1993; 100:185 9.
29. Ciprandi G, Buscaglia S. Pesce G et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95:612 21.
30. Bagnasco M, Canonica GW. Influence of H1-receptor antagonists on adhesion molecules and cellular traffic. Allergy 1995; 50(suppl 24): 17-23.
31. Pazdrak K, Gorski P, Ruta U. Inhibitory effect of levocabastine on allergen-induced increase of nasal reactivity to histamine and cell influx. Allergy 1993; 48:598 601.
32. Wegner CD, Gundel RH, Reilly P. Haynes N, Letts GL, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990; 247:456 9.
33. Buscaglia S, Catrullo A. Ciprandi G et al. Levocabastine eyedrops reduce ICAM-1 expression both in-vitro and in-vivo. Allergy 1995; 50 (suppl.):79.
34. Pronzato G, Ricca V, Varese P et al. Evaluation of antiallergic activity of azelastine nasal spray. Allergy 1995; 50 (suppl.):69.
35. Vignola AM, Crampette L, Mondain M et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-I and HLA-DR by nasal epithelial cells. Allergy 1995; 50:200 3.